ReviewCancer science2006
Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.
Review in Cancer science, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 134 citations in OpenAlex.
- Postnatal Cell-Type-Specific Localization of EGFR and Its Ligands (EGF, TGF-α and AREG) in the Rat Testis.Anatomia, histologia, embryologia · 2026Article
- Integrative Bioinformatic Analysis Identifies Key Genes Driving Breast Cancer Brain Metastasis.Diagnostics (Basel, Switzerland) · 2026Article
- Laminin-γ2-NR6A1 Fusion Protein Promotes Metastatic Potential in Non-Small-Cell Lung Carcinoma Cells without Epidermal Growth Factor Receptor Mutation.The American journal of pathology · 2025Article
- Article
- Inhibition of transforming growth factor-β signals suppresses tumor formation by regulation of tumor microenvironment networks.Cancer science · 2024Article
- Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review.Frontiers in microbiology · 2024Review
- Brain Vascular Microenvironments in Cancer Metastasis.Biomolecules · 2022Review
- Proteolytic modulation of tumor microenvironment signals during cancer progression.Frontiers in oncology · 2022Review
- Novel LAMC2 fusion protein has tumor-promoting properties in ovarian carcinoma.Cancer science · 2021Article
- Genes that Mediate Metastasis across the Blood-Brain Barrier.Trends in cancer · 2020Review
- CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.Cancer medicine · 2019Article
- Article
- VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas.European journal of histochemistry : EJH · 2019Article
- Extraembryonic heparin-binding epidermal growth factor-like growth factor deficiency compromises placentation in mice.Biology of reproduction · 2019Article
- Comprehensive analysis of normal adjacent to tumor transcriptomes.Nature communications · 2017Article
- BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.BMC cancer · 2017Article
- Article
- Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis.International journal of endocrinology · 2017Review
- Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.Targeted oncology · 2016Article
- Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-β pathways in MCF-7 Cancer cells with PX-866 and Raloxifene.Experimental cell research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HB-EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB-EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB-EGF. Recent studies have indicated that HB-EGF gene expression is significantly elevated in many human cancers and its expression level in a number of cancer-derived cell lines is much higher than those of other EGFR ligands. Several lines of evidence have indicated that HB-EGF plays a key role in the acquisition of malignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy. Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. CRM197, a specific inhibitor of HB-EGF, and an antibody against HB-EGF are both able to inhibit tumor growth in nude mice. These results indicate that HB-EGF is a promising target for cancer therapy, and that the development of targeting tools against HB-EGF could represent a novel type of therapeutic strategy, as an alternative to targeting ErbB receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.